Oramed Pharmaceuticals (ORMP) Income towards Parent Company (2011 - 2026)

Oramed Pharmaceuticals' Income towards Parent Company history runs 15 years deep, the most recent figure standing at $38.3 million for Q1 2026.

• Quarterly Income towards Parent Company rose 601.31% year-over-year to $38.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $121.2 million (up 528.42% YoY) and the FY2025 annual result came in at $75.2 million, up 493.67% from the prior year.
• Income towards Parent Company was $38.3 million for Q1 2026 at Oramed Pharmaceuticals, up from $21.2 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $48.4 million in Q3 2025 and bottomed at -$19.6 million in Q3 2024.
• A 5-year average of $3.3 million and a median of -$3.3 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2024 — Income towards Parent Company soared 800.99% — and 2025, when it sank 598.17%.
• Oramed Pharmaceuticals' Income towards Parent Company stood at -$12.1 million in 2022, then surged by 210.29% to $13.3 million in 2023, then plunged by 176.71% to -$10.2 million in 2024, then surged by 307.81% to $21.2 million in 2025, then jumped by 80.75% to $38.3 million in 2026.
• Business Quant data shows ORMP's Income towards Parent Company at $38.3 million in Q1 2026, $21.2 million in Q4 2025, and $48.4 million in Q3 2025.